BACKGROUND There has been a major revolution in the recommended treatment of hyperlipidaemia in patients with ischaemic heart disease following the publication of the Scandinavian Simvastatin Survival Study. This was the first major study to demonstrate that lipid-lowering drugs reduced mortality and morbidity in patients with ischaemic heart disease. AIM To evaluate the feasibility and cost-...

AIMS To examine the efficacy and safety of coadministered ezetimibe (EZE) with fenofibrate (FENO) in patients with mixed hyperlipidaemia. METHODS AND RESULTS This was a multicentre, randomized, double-blind, placebo-controlled, parallel arm trial in patients with mixed hyperlipidaemia [LDL-cholesterol (LDL-C), 3.4-5.7 mmol/L (2.6-4.7 mmol/L for patients with type 2 diabetes); triglycerides (T...

It has been well established that atherosclerosis begins in childhood. In the Bogalusa heart study, by the age of 15 years, 50% of young people had coronary fatty streaks, and by age 20, 33% had coronary atheroma. Therefore, prevention of atherosclerosis in the paediatric age group is of paramount importance. To understand lipid problems in children more clearly, one needs an understanding of l...

INTRODUCTION South Africa faces epidemics of HIV and non-communicable diseases (NCDs). The aim of this study was to characterize the prevalence of non-communicable disease risk factors and depression, stratified by HIV status, in a community with a high burden of HIV. METHODS We conducted a home-based HIV counselling and testing study in KwaZulu-Natal, South Africa between November 2011 and J...

BACKGROUND & OBJECTIVE Cholesteryl ester transfer protein (CETP) gene polymorphism is known to be associated with changes in lipid profiles. Primary hyperlipidaemia is considered to be a major risk factor for pancreatitis, atherosclerosis and coronary heart disease. We investigated the association of one common polymorphism in the CETP gene (Taq1B) with plasma lipid levels and CETP activity in ...